|
Market Closed -
Nyse
05:00:02 17/01/2026 HKT
|
5-day change
|
1st Jan Change
|
|
84.35 USD
|
-0.17%
|
 |
-0.27%
|
-1.06%
|
|
01-12 |
UBS Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Neutral Rating
|
MT
| |
01-12 |
Barclays Adjusts Price Target on Edwards Lifesciences to $104 From $103, Maintains Overweight Rating
|
MT
| |
01-12 |
Baird Adjusts Price Target on Edwards Lifesciences to $90 From $87, Maintains Neutral Rating
|
MT
| |
01-09 |
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $108 From $104, Maintains Buy Rating
|
MT
| |
01-09 |
TD Cowen Upgrades Edwards Lifesciences to Buy From Hold, Adjusts Price Target to $97 From $90
|
MT
| |
01-06 |
Evercore ISI Adjusts PT on Edwards Lifesciences to $94 From $92, Maintains Outperform Rating
|
MT
| |
12-19 |
North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2-
|
DJ
| |
12-18 |
JPMorgan Upgrades Edwards Lifesciences to Overweight From Neutral, Adjusts PT to $100 From $90
|
MT
| |
12-18 |
Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron…
|  | |
12-17 |
Canaccord Genuity Adjusts PT on Edwards Lifesciences to $87 From $89, Maintains Hold Rating
|
MT
| |
12-16 |
Baird Trims Price Target on Edwards Lifesciences to $87 From $88, Maintains Neutral Rating
|
MT
| |
12-11 |
Citigroup Adjusts Edwards Lifesciences Price Target to $101 From $96, Maintains Buy Rating
|
MT
| |
12-08 |
Leerink Partners Adjusts Edwards Lifesciences PT to $87 From $88, Maintains Market Perform Rating
|
MT
| |
12-06 |
Bernstein Adjusts Edwards Lifesciences Price Target to $95 From $90, Maintains Market Perform Rating
|
MT
| |
12-06 |
Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says
|
MT
| |
12-05 |
Raymond James Adjusts PT on Edwards Lifesciences to $100 From $96, Maintains Outperform Rating
|
MT
| |
12-05 |
UBS Adjusts Price Target on Edwards Lifesciences to $92 From $90, Maintains Neutral Rating
|
MT
| |
12-05 |
Truist Securities Adjusts PT on Edwards Lifesciences to $92 From $90, Maintains Hold Rating
|
MT
| |
12-05 |
RBC Raises Price Target on Edwards Lifesciences to $100 From $95, Keeps Outperform Rating
|
MT
| |
12-05 |
Stifel Adjusts Price Target on Edwards Lifesciences to $100 From $95, Maintains Buy Rating
|
MT
| |
12-05 |
BTIG Adjusts Price Target on Edwards Lifesciences to $103 From $100, Maintains Buy Rating
|
MT
| |
12-05 |
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $96 From $95, Maintains Overweight Rating
|
MT
| |
12-05 |
Barclays Adjusts Price Target on Edwards Lifesciences to $103 From $99, Maintains Overweight Rating
|
MT
| |
12-05 |
Canaccord Genuity Adjusts Price Target on Edwards Lifesciences to $89 From $84, Maintains Hold Rating
|
MT
| |
12-05 |
Baird Adjusts Price Target on Edwards Lifesciences to $88 From $83, Maintains Neutral Rating
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
